Amazon Biotech Incorporated
Sponsored Links
Biotechnology Companies
With contacts, email, phone & title Get company & employee information.
News and Blogs
Total : 1 View more »
Amazon Biotech Announces Appointment of New CEO and New Corporate Counsel
www.biospace.com | May 21, 2008
NEW YORK, NY--(Marketwire - May 21, 2008) - Amazon Biotech, Inc. (OTCBB: AMZO) (FRANKFURT: B2DA) announced that Mr. Eliyahu BenTal Tolchinsky has been appointed as director and Chief Executive Officer of the Company. </p><p>Mr. Tolchinsky, a graduate of Cornell University and Tulane Law School, has
http://www.biospace.com/news_story.aspx?StoryID=97501&full=1
Web Sites
Total : 29 View more »
Amazon Biotech
Amazon Biotech, Inc. Retains ROI Group Associates, Inc. as Investor Re Amazon Biotech, Inc. Retains ROI Group Associates, Inc. as Investor Relations Counsel Company Launches Nationwide Investor Outreach Program as It Is About to Enter Clinical Trials NEW YORK, ...
MacReport.Net - Today's Markets
BFAD, the Philippines Bureau of Food and Drugs, is the governmental body responsible for granting import licenses for foods and drugs into the Philippines.
Amazon Biotech Inc - Competitor Report - Market Research Reports - Research and Markets
The Amazon Biotech Inc Competitor Report includes a business summary, tabular representation of the number and percentage of products in each therapeutic indication, all company products listed with indication and stage of development, and competitors by therapeutic indication.
http://www.researchandmarkets.co.uk/reportinfo.asp?report_id=330223
Apria - resources - News
Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be used for the treatment of HIV/AIDS.
News from Zibb.com
Total : 2 View more »
Amazon Biotech Announces Postponement of Shareholder Meeting on 14A Filing - Zibb.com
NEW YORK, NY, Jul 17, 2008 (MARKET WIRE via COMTEX) --
Amazon Biotech, Inc. (PINKSHEETS: AMZO) (FRANKFURT: B2DA) announced that the 14A shareholder meeting set for July 17, 2008, to elect a three member Board of Directors and to address such other matters that may properly come before the meeting has been postponed in order to allow time to file a preliminary 14A ahead of the meeting on the 14A filing. The company will announce a new meeting date in the near future.
Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future with the goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials or enter the FDA Fast Track program to reach the marketplace. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com/.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.
Contact: LC Group Rick Lutz 404-261-1196 lcgroup@mindspring.com
SOURCE: Amazon Biotech, Inc.
mailto:lcgroup@mindspring.com
Tags: aids biotechnology clinical drugs fda frankfurt hiv joint venture market pharmaceuticals products sales securities track
Companies: Amazon Biotech Inc (AMZO)
Amazon Biotech Announces Filing of 14A to Set Shareholder Meeting - Zibb.com
NEW YORK, NY, Sep 26, 2008 (MARKET WIRE via COMTEX) --
Amazon Biotech, Inc. (PINKSHEETS: AMZO) (FRANKFURT: B2DA) announced that a preliminary 14A was filed by Amazon to set a shareholder meeting, at a time to be announced, to elect a three member Board of Directors and to address such other matters as may properly come before the meeting or any adjournments thereof.
Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future with the goal of attracting a joint venture partner with a major pharmaceutical company in Phase III trials or enter the FDA Fast Track program to reach the marketplace. Amazon Biotech specializes in natural plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com/.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.
Contact: LC Group Rick Lutz 404-261-1196 lcgroup@mindspring.com
SOURCE: Amazon Biotech, Inc.
mailto:lcgroup@mindspring.com
Tags: aids biotechnology clinical drugs fda frankfurt hiv joint venture market pharmaceuticals products sales securities track
Companies: Amazon Biotech Inc (AMZO)
News from Zibb.com
Explore Related Products
Explore in Related Industries
- Amazon Biotech Incorporated in:
- Healthcare & Medicine (18)
- Finance & Tax (13)
- Chemicals, Plastics & Rubber (5)
- General Business (1)
